374 results in Exploration of Targeted Anti-tumor Therapy
Latest
  • Latest
  • Most Viewed
  • Most Downloaded
  • Most Cited
Sort by :
Open Access Review
The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma
Alessia Ciafarone, Paola Palumbo
Published: May 21, 2026 Explor Target Antitumor Ther. 2026;7:1002374
64 5 0
Open Access Review
RNA therapeutic targeting of recalcitrant and rare cancers
Afeez Adekunle Ishola ... Bashir Lawal
Published: May 21, 2026 Explor Target Antitumor Ther. 2026;7:1002373
61 5 0
Open Access Review
Triple-negative breast cancer: current understanding and future perspectives
Alhasan Alobaidi, Vikrant Rai
Published: May 14, 2026 Explor Target Antitumor Ther. 2026;7:1002372
449 15 0
Open Access Original Article
Oligometastatic versus polymetastatic colon cancer: functional and genomic determinants of divergent metastatic trajectories
Roberto Sirica ... Alessandro Ottaiano
Published: May 13, 2026 Explor Target Antitumor Ther. 2026;7:1002371
227 17 0
Open Access Mini Review
The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability
Carminia Maria Della Corte ... Floriana Morgillo
Published: April 27, 2026 Explor Target Antitumor Ther. 2026;7:1002370
1394 43 0
Open Access Commentary
FDA 2025 Cancer Drug Approvals: targeted therapy dominates
Jan Trøst Jørgensen
Published: April 27, 2026 Explor Target Antitumor Ther. 2026;7:1002369
3013 38 0
Open Access Systematic Review
The evolving role of targeted radioligand therapy in small cell and non-small cell lung cancer: a systematic review
Serin Moghrabi ... Akram Al-Ibraheem
Published: April 27, 2026 Explor Target Antitumor Ther. 2026;7:1002368
872 20 0
Open Access Case Report
Solitary fibrous tumor of the lung: diagnostic challenges and surgical management
Vasileios Leivaditis ... Manfred Dahm
Published: April 21, 2026 Explor Target Antitumor Ther. 2026;7:1002367
422 17 0
Open Access Original Article
Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia
Sergey V. Orlov ... Evgeny N. Imyanitov
Published: April 16, 2026 Explor Target Antitumor Ther. 2026;7:1002366
872 28 0
Open Access Original Article
Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC
Yuki Oda ... Kiyohide Fujimoto
Published: April 13, 2026 Explor Target Antitumor Ther. 2026;7:1002365
978 18 0
Open Access Original Article
Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition
Maellis Payet-Desruisseaux ... Borhane Annabi
Published: March 30, 2026 Explor Target Antitumor Ther. 2026;7:1002364
931 20 0
Open Access Original Article
CHD4 and NOX4 expression in thyroid tumor tissues
Salma Fenniche ... Rabii Ameziane El Hassani
Published: March 25, 2026 Explor Target Antitumor Ther. 2026;7:1002363
895 29 0
Open Access Original Article
Survival prediction in triple-negative breast cancer: a Cox model with fairness assessment using ISO/IEC TR 24027:2021 in a MENA cohort
Mehrshad Alirezaei Farahani ... Marjan Mansourian
Published: March 20, 2026 Explor Target Antitumor Ther. 2026;7:1002362
1234 21 0
Open Access Systematic Review
Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis
Shree Rath ... Amar Lal
Published: February 27, 2026 Explor Target Antitumor Ther. 2026;7:1002360
1758 39 0
Open Access Mini Review
Benign, persistent, and invasive: mechanistic and translational approaches to middle‑ear cholesteatoma
Pinelopi Samara ... Ioannis Athanasopoulos
Published: February 24, 2026 Explor Target Antitumor Ther. 2026;7:1002359
1572 36 0
Open Access Perspective
Application of explainable artificial intelligence integrating with electronic health record in oncology
Yuhan Yang, Xici Liu
Published: February 04, 2026 Explor Target Antitumor Ther. 2026;7:1002357
2869 19 2
Open Access Editorial
The critical need for robust decision support in the era of precision cancer therapeutics
Maurie Markman
Published: January 22, 2026 Explor Target Antitumor Ther. 2026;7:1002356
1047 41 0
Open Access Review
Next-generation nanocarriers for precision antitumor therapy: from passive targeting to intelligent response
Dilpreet Singh, Akshay Kumar
Published: December 28, 2025 Explor Target Antitumor Ther. 2025;6:1002355
3314 57 6